Takeda Pharmaceutical (NYSE:TAK) General Counsel Sells $527,842.80 in Stock

Takeda Pharmaceutical Co. (NYSE:TAK) General Counsel Natalie Anne Marie Furney sold 30,868 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $17.10, for a total transaction of $527,842.80. Following the sale, the general counsel owned 204,298 shares of the company’s stock, valued at approximately $3,493,495.80. This represents a 13.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Takeda Pharmaceutical Stock Performance

Shares of TAK opened at $17.64 on Friday. The company has a market capitalization of $56.53 billion, a PE ratio of 51.89 and a beta of -0.08. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.62 and a current ratio of 1.14. The company’s 50 day moving average price is $16.57 and its 200 day moving average price is $17.14. Takeda Pharmaceutical Co. has a 52 week low of $12.99 and a 52 week high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Tuesday, March 31st. The company reported $0.56 earnings per share (EPS) for the quarter. Takeda Pharmaceutical had a net margin of 3.80% and a return on equity of 10.95%. The company had revenue of $6.90 billion during the quarter. Research analysts expect that Takeda Pharmaceutical Co. will post 0.32 EPS for the current fiscal year.

Hedge Funds Weigh In On Takeda Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in Takeda Pharmaceutical by 14.2% in the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock worth $55,358,000 after acquiring an additional 370,800 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Takeda Pharmaceutical during the 4th quarter worth $998,000. Quantinno Capital Management LP raised its holdings in shares of Takeda Pharmaceutical by 20.6% during the 1st quarter. Quantinno Capital Management LP now owns 1,289,326 shares of the company’s stock valued at $23,878,000 after purchasing an additional 219,999 shares in the last quarter. Bleakley Financial Group LLC raised its holdings in shares of Takeda Pharmaceutical by 19.0% during the 1st quarter. Bleakley Financial Group LLC now owns 431,602 shares of the company’s stock valued at $7,993,000 after purchasing an additional 68,844 shares in the last quarter. Finally, Sivia Capital Partners LLC acquired a new stake in shares of Takeda Pharmaceutical in the 2nd quarter valued at $351,000. Institutional investors own 9.17% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Zacks Research upgraded Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, Weiss Ratings cut Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, July 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold”.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.